Amgen (AMGN) DIvidends Date & History

Key Takeaways

• Amgen offers a current dividend yield of approximately 2.74% with an annualized payout of $10.08 per share.
• The company pays dividends quarterly and has raised its dividend for 13 consecutive years.
• The payout ratio stands at roughly 67%, indicating solid earnings coverage.
• Amgen maintains a consistent dividend growth strategy supported by strong free cash flow.
• The stock appeals to dividend growth investors seeking moderate yield with reliable increases.
• Yield compares favorably to the broader pharmaceutical and biotechnology industry median.

Dividend Overview

Amgen Inc. (AMGN) follows a quarterly dividend payment schedule. The current annualized dividend totals $10.08 per share, delivering a forward yield near 2.74%. The most recent quarterly dividend stands at $2.52 per share. Amgen qualifies as a dividend growth stock rather than a high-yield name, with a track record of steady increases that supports long-term income compounding. The policy reflects a balanced approach prioritizing sustainable payouts alongside reinvestment in research and development.

Dividend History and Growth

Amgen has increased its dividend annually for 13 consecutive years. Quarterly payouts rose from $2.38 in 2025 to $2.52 in 2026, reflecting measured growth. The five-year compound annual growth rate approximates 8.05%, while recent one-year growth reached about 5.81%. Payments remain consistent on a quarterly basis with no cuts in the recent history. This streak demonstrates management's commitment to returning capital to shareholders while funding innovation in biotechnology.

Dividend Sustainability and Payout Ratio

Amgen's payout ratio of approximately 67% suggests the dividend is well covered by earnings. Free cash flow provides additional support for ongoing payments and potential future increases. The company maintains a conservative balance sheet with manageable debt levels relative to its cash generation. No immediate risks to sustainability appear evident, as earnings and cash flow comfortably exceed dividend obligations. Future dividends remain subject to board approval.

Dividend Compared to Industry Peers

Amgen's yield of roughly 2.74% exceeds the pharmaceutical and biotechnology industry median of about 2.38%. Peers in the sector often feature lower or variable payouts due to heavy research spending. Amgen stands out for its consistent growth streak and moderate yield, positioning it as a more income-oriented option within the biotech space compared to many growth-focused competitors.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover opportunities tailored to your strategy.

Is This Stock Attractive for Dividend Investors?

Amgen may suit dividend growth investors who prioritize consistent annual increases over high current yield. Income-focused investors could find the quarterly payments and 2.74% yield appealing for portfolio diversification within healthcare. Long-term conservative investors may value the 13-year growth streak and earnings coverage, which support sustainability. The stock offers moderate income with growth potential, though it carries typical sector risks such as regulatory changes and research outcomes. Investors seeking higher yields might consider other sectors, while those favoring stability could view Amgen as a balanced holding.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations